PT -期刊文章盟伊丽莎白·库恩AU -奥黛丽Perrotin盟Renaud拉抱着非盟-雪绒花Touron AU -苏菲Dautricourt盟马修Vanhoutte AU -丹尼斯薇薇安盟文森特de La Sayette AU -盖尔Chetelat盟的阿尔茨海默病的神经影像学的TI -协会Informant-Reported与认知和大脑记忆衰退恶化通过老年痴呆症临床连续援助- 10.1212 / WNL。0000000000207338 DP - 2023年6月13日TA -神经病半岛投注体育官网学PG - e2454 e2465 VI - 100 IP - 24 4099 - //www.ebmtp.com/content/100/24/e2454.short 4100 - //www.ebmtp.com/content/100/24/e2454.full所以Neurology2023 6月13;100 AB -背景和目标研究稀疏关于之间的关联informant-reported主观记忆衰退(线人报告)和阿尔茨海默病(AD)生物标记。因此本研究旨在确定的临床相关性线人报告整个广告临床连续体,通过评估其特定的与淀粉样蛋白沉积的关系,认知和神经退化。方法从Imagerie参与者Multimodale de la病d 'Alzheimer联合国施塔德Precoce (IMAP +)初级群体和阿尔茨海默病神经影像倡议(ADNI)复制队列中;进行了多通道神经影像学和神经心理评估。后续数据IMAP +参与者/ 36个月也用于纵向分析。线人报告测量的认知困难量表(IMAP +)和日常认知(ADNI)。一般线性模型被用来评估之间的横向联系线人报告和淀粉pet,认知表现,和神经退行性变的老年痴呆症的签名(萎缩和代谢减退);而纵向联系在IMAP +线性mixed-effects模型评估。结果总共包括110 IMAP +参与者,包括32个认知未受损伤的老年人(控制、年龄:70.91±6.57岁,女:50%),25名患者主观认知能力下降(SCD, 65.88±6.64, 40%)、35岁患有轻度认知障碍(MCI, 72.49±7.5, 34%)和18 Alzheimer-type痴呆(AD痴呆,68.17±8.59,28%)。七百三十一包括ADNI参与者,包括157名对照(74.21±5.95,55%),84年SCD(72.00±5.41, 63%), 369年与MCI(71.84±7.4, 44%),和121 AD痴呆(74.29±7.75,40%)。 In IMAP+, a higher informant report strongly correlated to greater amyloid-PET, specifically in patients with MCI (β = 0.48, p = 0.003), and to lower cognitive performance in patients with SCD (global cognition, β = −0.41, p = 0.04) and MCI (memory, β = −0.37, p = 0.03). Findings in patients with MCI were replicated in the ADNI (amyloid-PET, β = 0.25, p < 0.001; memory, β = −0.22, p < 0.001) and extended to neurodegeneration in AD signature areas (β = −0.2, p < 0.001). Longitudinal analyses in IMAP+ showed links with global cognitive decline over time in patients with MCI (estimate −0.74, SE 0.26, p = 0.005) and SCD (estimate −0.36, SE 0.26, p = 0.02) where a higher baseline informant report also predicted an increased amyloid-PET over time (estimate 0.008, SE 0.003, p = 0.02).Discussion Altogether, our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD.Trial Registration Information ClinicalTrials.gov Identifier: NCT01638949.AD dementia=Alzheimer-type dementia; ADNI=Alzheimer Disease Neuroimaging Initiative; CDS=Cognitive Difficulties Scale; CU=cognitively unimpaired; ESR=Encoding, Storage, and Retrieval; FDG=18F-fluorodeoxyglucose; FDR=false discovery rate; FLAIR=fluid-attenuated inversion recovery; GM=gray matter; IMAP+=Imagerie Multimodale de la maladie d'Alzheimer à un stade Précoce; I-SMD=Informant-reported Subjective Memory Decline; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; SCD=subjective cognitive decline; Self-SMD=self-reported Subjective Memory Decline; SUVr=global neocortical standardized uptake value ratio